DK2310046T3 - Hidtil ukendte adjuvanssammensætninger - Google Patents

Hidtil ukendte adjuvanssammensætninger Download PDF

Info

Publication number
DK2310046T3
DK2310046T3 DK09769768.4T DK09769768T DK2310046T3 DK 2310046 T3 DK2310046 T3 DK 2310046T3 DK 09769768 T DK09769768 T DK 09769768T DK 2310046 T3 DK2310046 T3 DK 2310046T3
Authority
DK
Denmark
Prior art keywords
adjustive
unknown
compositions
unknown adjustive
adjustive compositions
Prior art date
Application number
DK09769768.4T
Other languages
English (en)
Inventor
Cedo Martin Bagi
Tedd Alan Childers
Paul Joseph Dominowski
Richard Lee Krebs
Ramasamy Mannar Mannan
Mary Kathryn Olsen
James Richard Thompson
Risini Dhammika Weeratna
Robert John Yancey Jr
Shucheng Zhang
Sangita Mediratta
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Application granted granted Critical
Publication of DK2310046T3 publication Critical patent/DK2310046T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/012—Coccidia antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24351—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
DK09769768.4T 2008-06-27 2009-06-24 Hidtil ukendte adjuvanssammensætninger DK2310046T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7623208P 2008-06-27 2008-06-27
US21455709P 2009-04-24 2009-04-24
PCT/IB2009/052724 WO2009156960A2 (en) 2008-06-27 2009-06-24 Novel adjuvant compositions

Publications (1)

Publication Number Publication Date
DK2310046T3 true DK2310046T3 (da) 2016-04-25

Family

ID=41445049

Family Applications (2)

Application Number Title Priority Date Filing Date
DK09769768.4T DK2310046T3 (da) 2008-06-27 2009-06-24 Hidtil ukendte adjuvanssammensætninger
DK15197967.1T DK3056214T3 (da) 2008-06-27 2009-06-24 Hidtil ukendte adjuvanssammensætninger

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK15197967.1T DK3056214T3 (da) 2008-06-27 2009-06-24 Hidtil ukendte adjuvanssammensætninger

Country Status (29)

Country Link
US (6) US8580280B2 (da)
EP (4) EP3552625A1 (da)
JP (5) JP5659332B2 (da)
KR (1) KR101333852B1 (da)
CN (4) CN104758929B (da)
AR (1) AR072378A1 (da)
AU (1) AU2009263759B2 (da)
BR (2) BRPI0913954B1 (da)
CA (3) CA2960846C (da)
CL (1) CL2010001360A1 (da)
CO (1) CO6331297A2 (da)
CY (2) CY1117650T1 (da)
DK (2) DK2310046T3 (da)
ES (2) ES2569907T3 (da)
HR (1) HRP20190876T1 (da)
HU (2) HUE043493T2 (da)
LT (1) LT3056214T (da)
ME (1) ME01199B (da)
MX (6) MX2010014026A (da)
NZ (5) NZ727616A (da)
PH (2) PH12014501836A1 (da)
PL (2) PL2310046T3 (da)
PT (1) PT3056214T (da)
RU (1) RU2510280C2 (da)
SI (2) SI3056214T1 (da)
TW (4) TWI622400B (da)
UY (1) UY31942A (da)
WO (1) WO2009156960A2 (da)
ZA (1) ZA201007835B (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8444989B1 (en) * 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
MX2010014026A (es) * 2008-06-27 2011-02-15 Pfizer Composiciones adyuvantes novedosas.
TWI351288B (en) * 2008-07-04 2011-11-01 Univ Nat Pingtung Sci & Tech Cpg dna adjuvant in avian vaccines
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
HUE027823T2 (hu) 2008-12-09 2016-11-28 Coley Pharm Group Inc Immunstimuláló oligonukleotidok
CN107582526A (zh) * 2009-08-12 2018-01-16 希格默伊德药业有限公司 包含聚合物基质和油相的免疫调节组合物
FR2957803B1 (fr) * 2010-03-24 2012-06-01 Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic Diluants adjuvants de vaccins vivants pour maladies porcines
NZ603527A (en) * 2010-05-28 2014-10-31 Zoetis Belgium S A Vaccines comprising cholesterol and cpg as sole adjuvant - carrier molecules
MX345704B (es) 2011-06-10 2017-02-10 Novartis Tiergesundheit Ag Vacuna bovinas y métodos.
US10047116B2 (en) * 2011-10-03 2018-08-14 Mx Adjuvac Ab Nanoparticles, process for preparation and use thereof as carrier for amphipatic and hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
CA2866170A1 (en) 2012-03-12 2013-09-19 Advanced Bioadjuvants, Llc Adjuvant and vaccine compositions
AU2013370982C9 (en) * 2012-12-28 2019-01-24 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition comprising mycoplasma antigens
MX361273B (es) 2012-12-28 2018-12-03 Boehringer Ingelheim Vetmedica Gmbh Metodo para obtener una vacuna de mycoplasma.
CN103127495B (zh) * 2013-01-28 2015-04-08 重庆市畜牧科学院 二联灭活苗的制剂及其制备方法
MX2016002903A (es) * 2013-09-05 2016-06-06 Zoetis Services Llc Composiciones inmunogenas de la glicoproteina g de los virus hendra y nipah.
KR101943171B1 (ko) 2013-09-19 2019-01-29 조에티스 서비시즈 엘엘씨 유성 아쥬반트
AU2014337452A1 (en) 2013-10-17 2016-04-21 Zoetis Services Llc Methods and compositions for treatment of S. equi infection
EP4241853B1 (en) 2013-11-26 2026-02-11 Zoetis Services LLC Compositions for induction of immune response
PL3223846T3 (pl) * 2014-11-26 2024-03-11 Huvepharma, Inc. Kompozycje adiuwantowe i powiązane sposoby
US10195261B2 (en) 2014-11-26 2019-02-05 VaxLiant, LLC Adjuvant compositions and related methods
DK3244920T5 (da) 2015-01-16 2024-10-07 Zoetis Services Llc Mund- og klovsyge-vaccine
US9636397B2 (en) * 2015-03-24 2017-05-02 VaxLiant, LLC Adjuvant compositions and related methods
CN104771754B (zh) * 2015-04-02 2018-02-13 武汉科前生物股份有限公司 一种猪圆环病毒2型灭活疫苗水性佐剂及应用
CN106267183B (zh) * 2015-06-09 2023-02-28 普莱柯生物工程股份有限公司 含有佐剂的活疫苗组合物及其制备方法和应用
CN106344920B (zh) * 2015-07-16 2020-11-27 普莱柯生物工程股份有限公司 一种疫苗用佐剂及其应用
US10456459B2 (en) 2015-07-20 2019-10-29 Zoetis Services Llc Liposomal adjuvant compositions
AU2016297529B2 (en) * 2015-07-20 2021-09-09 Zoetis Services Llc Liposomal adjuvant compositions
SG10201913547YA (en) * 2015-10-19 2020-02-27 Cadila Healthcare Ltd New adjuvant and vaccine composition containing the same
EP3402878A1 (en) 2016-01-11 2018-11-21 Zoetis Services LLC Novel cross protective vaccine compositions for porcine epidemic diarrhea virus
EP3432922B1 (en) 2016-03-21 2020-02-19 South Dakota Board of Regents Orf virus-based platform for vaccine delivery
MX2018014857A (es) 2016-06-02 2019-03-07 Zoetis Services Llc Vacuna contra la bronquitis infecciosa.
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
GB201703529D0 (en) 2017-03-06 2017-04-19 Cambridge Entpr Ltd Vaccine composition
US10092604B1 (en) * 2017-12-21 2018-10-09 Bioceuticals Pte. Ltd. Methods for treatment of skin infectious diseases using microorganisms
AU2019236328B2 (en) 2018-03-16 2025-10-09 Zoetis Services Llc Peptide vaccines against Interleukin-31
CN108853493A (zh) * 2018-07-26 2018-11-23 中国人民解放军陆军军医大学 麦冬皂苷d及其纳米乳在制备疫苗佐剂中的应用
WO2020023950A1 (en) 2018-07-27 2020-01-30 Research Development Foundation Chimeric immunogenic polypeptides
WO2020055503A1 (en) * 2018-09-14 2020-03-19 Massachusetts Institute Of Technology Nanoparticle vaccine adjuvant and methods of use thereof
CN109675028A (zh) * 2019-03-01 2019-04-26 龙阔（苏州）生物工程有限公司 疫苗佐剂及其制备方法和应用及猪繁殖与呼吸综合征疫苗
AU2020314625A1 (en) * 2019-07-12 2022-02-03 Research Development Foundation Ehrlichia vaccines and immunogenic compositions
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US20230263815A1 (en) 2020-06-19 2023-08-24 Kimberly-Clark Worldwide, Inc. Saponin containing extracts prepared from hesperaloe useful in the treatment of non-human animals
CA3182453A1 (en) * 2020-06-19 2021-12-23 Ning Wei Saponin containing extracts prepared from hesperaloe useful in the treatment of non-human animals
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
TWI884296B (zh) * 2020-08-11 2025-05-21 美商碩騰服務公司 抗冠狀病毒疫苗
CN114848807A (zh) * 2021-02-04 2022-08-05 洛阳赛威生物科技有限公司 一种蜂胶佐剂组合物、及其制备方法以及应用
US20230109193A1 (en) * 2021-10-02 2023-04-06 Massachusetts Institute Of Technology Synergistic Combination of Alum and Non-Liposome, Non-Micelle Particle Vaccine Adjuvants
CN120712079A (zh) * 2023-02-16 2025-09-26 瓦希纳诺公司 包含用于在没有任何佐剂的情况下经由阳离子多糖纳米颗粒递送灭活的完整细菌的系统的疫苗组合物
WO2025006564A1 (en) 2023-06-26 2025-01-02 Research Development Foundation Immunoreactive peptides
CN116747312B (zh) * 2023-07-21 2025-08-08 辽宁成大生物股份有限公司 一种疫苗冻干保护剂、制剂及制备方法
CN121360223A (zh) * 2024-07-19 2026-01-20 硕腾服务有限责任公司 流感疫苗

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4264587A (en) * 1979-08-01 1981-04-28 Pedersen Niels C Vaccine for preventing persistent feline leukemia viremia in cats
NZ221306A (en) * 1986-08-15 1990-02-26 Commw Scient Ind Res Org 2-component immunoadjuvant comprising a mycobacterial free immunoadjuvant oil and a polycationic polyelectrolyte immunoadjuvant and vaccines thereof
US5084269A (en) 1986-11-06 1992-01-28 Kullenberg Fred W Adjuvant for dose treatment with antigens
ES2037072T3 (es) 1986-12-19 1993-06-16 Duphar International Research B.V Suspension coadyuvante estabilizada que comprende bromuro de dimetil-dioctadecil-amonio.
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
RU1615918C (ru) 1989-05-22 1995-07-09 Всероссийский научно-исследовательский институт защиты животных Адъювант
JPH07502897A (ja) * 1992-01-06 1995-03-30 ファイザー・インコーポレイテッド ネコ白血病ウイルスワクチン
ZA936095B (en) 1992-08-21 1994-03-14 Univ Melbourne Cytokine applications.
US6764682B1 (en) 1994-06-16 2004-07-20 Aventis Pasteur Limited Adjuvant compositions containing more than one adjuvant
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6846489B1 (en) * 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
ES2241042T3 (es) 1996-10-11 2005-10-16 The Regents Of The University Of California Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
EP0855184A1 (en) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
BR9809426A (pt) 1997-04-30 2000-06-13 Merieux Oravax Composição de vacina anti-helicobacter para uso pela via sistêmica subdiafragmática e método de imunização mucosal/parenteral combinado
CA2289702C (en) 1997-05-14 2008-02-19 Inex Pharmaceuticals Corp. High efficiency encapsulation of charged therapeutic agents in lipid vesicles
WO1998055495A2 (en) 1997-06-06 1998-12-10 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
EP1032416B1 (en) * 1997-10-20 2007-01-24 Bayer Corporation Neospora vaccines
EP0953641A3 (en) * 1998-03-26 2002-03-13 Pfizer Products Inc. Polynucleotide molecules encoding neospora proteins
ATE305507T1 (de) 1998-05-14 2005-10-15 Coley Pharm Gmbh Verfahren zur regulierung der hematopoiese mit hilfe von cpg oligonukleotide
PT1077722E (pt) 1998-05-22 2006-12-29 Coley Pharm Group Inc Produtos e composições para utilização na indução da imunidade mucosal
US20040247662A1 (en) 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
US7049302B1 (en) 1998-08-10 2006-05-23 Antigenics Inc. Compositions of CPG and saponin adjuvants and uses thereof
AU769539B2 (en) 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
US8206749B1 (en) 1999-02-26 2012-06-26 Novartis Vaccines And Diagnostics, Inc. Microemulsions with adsorbed macromolecules and microparticles
WO2000061184A2 (en) 1999-04-08 2000-10-19 Glenn Gregory M Dry formulation for transcutaneous immunization
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
DE60014076T2 (de) 1999-04-19 2005-10-13 Glaxosmithkline Biologicals S.A. Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid
WO2000067023A1 (en) 1999-04-29 2000-11-09 Coley Pharmaceutical Gmbh Screening for immunostimulatory dna functional modifyers
EP1322655B1 (en) 2000-01-14 2007-11-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Oligodeoxynucleotide and its use to induce an immune response
EP1311288A1 (en) 2000-01-20 2003-05-21 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
ES2248283T3 (es) 2000-02-21 2006-03-16 Pharmexa A/S Nuevo procedimiento para reducir los niveles de amiloide.
AU5736601A (en) 2000-05-01 2001-11-12 Hybridon Inc Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
GB0025577D0 (en) 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
ATE398175T1 (de) 2000-12-08 2008-07-15 Coley Pharmaceuticals Gmbh Cpg-artige nukleinsäuren und verfahren zu ihrer verwendung
US7244438B2 (en) 2001-01-05 2007-07-17 Intercell Ag Uses for polycationic compounds
US7713942B2 (en) 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
CA2439111A1 (en) 2001-04-05 2002-10-17 Chiron Corporation Mucosal boosting following parenteral priming
US7105495B2 (en) 2001-04-30 2006-09-12 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
JP4188092B2 (ja) 2001-05-21 2008-11-26 インターツェル・アクチェンゲゼルシャフト 免疫促進性オリゴデオキシ核酸分子
EP1395262A4 (en) * 2001-06-15 2006-04-12 Ribapharm Corp NUCLEOSIDE-VACCINE-ADJUVANTS
EP2027873B8 (en) * 2001-07-02 2015-11-11 Zoetis Services LLC One dose vaccination with mycoplasma hyopneumoniae
CN1612749A (zh) * 2001-07-02 2005-05-04 辉瑞产品公司 用于减弱牲畜体内牛支原体肺炎的猪肺炎支原体疫苗和方法
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
EP1501359A4 (en) 2001-08-03 2007-04-18 Celldex Therapeutics Inc IMMUNOSTIMULATING OLIGONUCLEOTIDE-CONTAINING COMPOSITIONS AND USES THEREOF FOR IMPROVING FC-RECEPTOR-MEDIATED IMMUNOTHERAPIES
JP4607452B2 (ja) 2001-08-07 2011-01-05 ダイナバックス テクノロジーズ コーポレイション 免疫調節性組成物、製剤およびその使用方法
US20030138434A1 (en) 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
IL160157A0 (en) 2001-08-17 2004-07-25 Coley Pharm Group Inc Combination motif immune stimulation oligonucleotides with improved activity
CA2457514A1 (en) 2001-08-28 2003-03-06 Pfizer Products Inc. Mycoplasma bovis challenge model, methods for administering m.bovis and methods for inducing pneumonic lung lesions
AU2002339224B2 (en) 2001-09-14 2008-10-09 Kuros Us Llc Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
WO2004012669A2 (en) 2002-08-01 2004-02-12 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides
US20030119774A1 (en) 2001-09-25 2003-06-26 Marianna Foldvari Compositions and methods for stimulating an immune response
GB0123580D0 (en) 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
JP2005508945A (ja) 2001-10-06 2005-04-07 メリアル リミテッド Ｃｐｇ配合物及び関連方法
US7276489B2 (en) 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
JP2005516897A (ja) 2001-11-07 2005-06-09 イネックス ファーマシューティカルズ コーポレイション 改善された粘膜のワクチン及びその使用方法
JP2005519035A (ja) 2001-12-07 2005-06-30 インターツェル・アクチェンゲゼルシャフト 免疫促進性オリゴデオキシヌクレオチド
EP1474432A1 (en) 2002-02-04 2004-11-10 Biomira Inc. Immunostimulatory, covalently lipidated oligonucleotides
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
CA2476854A1 (en) 2002-02-19 2003-08-28 Syntherica Corporation Surrogate antibodies and methods of preparation and use thereof
US8153141B2 (en) 2002-04-04 2012-04-10 Coley Pharmaceutical Gmbh Immunostimulatory G, U-containing oligoribonucleotides
AU2003262379A1 (en) 2002-04-16 2003-11-03 Auburn University TRANSIENT AND/OR PERMANENT MODIFICATION OF SEXUAL BEHAVIOR AND/OR FERTILITY USING RECOMBINANT CHIMERIC GnRH
CN101160399A (zh) 2002-04-22 2008-04-09 拜奥尼茨生命科学公司 寡核苷酸组合物及其在调节免疫应答中的应用
KR100456681B1 (ko) 2002-05-22 2004-11-10 주식회사 대웅 박테리아의 염색체 ｄｎａ 파쇄물과 비독성리포폴리사카라이드를 포함하는 면역강화 및 조절 조성물
JP2005528899A (ja) 2002-05-28 2005-09-29 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 抗原提示細胞の生成方法
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
SE0201701D0 (sv) 2002-06-05 2002-06-05 Gotovax Ab Treatment of epithelial tumors and infections
WO2003103586A2 (en) 2002-06-05 2003-12-18 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids
NZ539746A (en) 2002-11-05 2008-03-28 James Hardie Int Finance Bv Method and apparatus for producing calcium silicate hydrate
PL378001A1 (pl) * 2003-01-29 2006-02-20 Pfizer Products Inc. Szczepionki przeciw Bordetella bronchiseptica dla psów
AU2003900767A0 (en) * 2003-02-21 2003-03-13 St Vincent's Hospital Sydney Limited Idiotypic vaccine
EP1605972A2 (en) 2003-03-26 2005-12-21 Cytos Biotechnology AG Hiv-peptide-carrier-conjugates
KR100720213B1 (ko) 2003-04-04 2007-05-21 화이자 프로덕츠 인코포레이티드 미세 유동화된 수중 유적형 유화액 및 백신 조성물
SE0301998D0 (sv) * 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
GB0323965D0 (en) * 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
WO2005107797A1 (en) 2004-03-09 2005-11-17 Chiron Corporation Influenza virus vaccines
AU2005230708B2 (en) * 2004-04-05 2009-01-15 Zoetis Services Llc Microfluidized oil-in-water emulsions and vaccine compositions
CA2583061C (en) * 2004-10-06 2015-02-17 Kwang Guan Tay Antibody production method
GB0426481D0 (en) * 2004-12-02 2005-01-05 Vaccine Technology Ltd Composition
AU2006231916A1 (en) * 2005-04-07 2006-10-12 Pharmacia & Upjohn Company Llc Formulations and process for production of Bordetella bronchiseptica p68 antigen and vaccines
WO2006116458A2 (en) * 2005-04-26 2006-11-02 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhances immunostimulatory activity
PH12011502633A1 (en) * 2005-10-07 2012-11-12 Zoetis P Llc Vaccines and methods to treat canine influenza
WO2008051245A2 (en) * 2005-12-02 2008-05-02 Novartis Ag Nanoparticles for use in immunogenic compositions
ME00045B (me) * 2006-01-26 2010-10-10 Zoetis Services Llc Nove kompozicije glikolipidnog adjuvansa
CA2637837A1 (en) * 2006-01-26 2007-08-09 Hx Diagnostics, Inc. Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof
KR20090088944A (ko) * 2006-12-15 2009-08-20 쉐링-프라우 리미티드 배양물 속에서 인플루엔자 바이러스를 복제하는 방법
WO2008074487A2 (en) * 2006-12-19 2008-06-26 Novosom Ag Lipids and lipid assemblies comprising transfection enhancer elements
US20080292663A1 (en) 2007-05-22 2008-11-27 Gerber Jay D Adjuvant compositions and methods for delivering vaccines
CL2008001806A1 (es) 2007-06-20 2008-09-05 Wyeth Corp Composicion de vacuna en emulsion agua en aceite que comprende un antigeno y un adyuvante en la fase acuosa; y metodo de elaboracion.
MX2010014026A (es) * 2008-06-27 2011-02-15 Pfizer Composiciones adyuvantes novedosas.
JP6008345B2 (ja) 2009-02-27 2016-10-19 東レ株式会社 免疫原性組成物
US10456459B2 (en) * 2015-07-20 2019-10-29 Zoetis Services Llc Liposomal adjuvant compositions

Also Published As

Publication number Publication date
CN104001169B (zh) 2016-03-23
EP2310046A2 (en) 2011-04-20
JP6294938B2 (ja) 2018-03-14
UY31942A (es) 2010-01-29
HRP20190876T1 (hr) 2019-07-12
WO2009156960A9 (en) 2010-09-30
EP3725328A3 (en) 2020-12-23
MX2019011253A (es) 2019-11-01
CA2723786A1 (en) 2009-12-30
SI3056214T1 (sl) 2019-06-28
TWI622400B (zh) 2018-05-01
CO6331297A2 (es) 2011-10-20
BRPI0913954A2 (pt) 2021-04-06
US10238736B2 (en) 2019-03-26
CN104001169A (zh) 2014-08-27
PH12014501835A1 (en) 2016-03-07
NZ709547A (en) 2017-01-27
CA2960734A1 (en) 2009-12-30
NZ602945A (en) 2014-05-30
TW201544121A (zh) 2015-12-01
AU2009263759A1 (en) 2009-12-30
CN104001170B (zh) 2016-08-24
NZ589079A (en) 2012-11-30
CN104758929B (zh) 2018-05-25
CN102076358B (zh) 2016-08-17
HUE028921T2 (en) 2017-01-30
ES2728949T3 (es) 2019-10-29
KR20110010817A (ko) 2011-02-07
EP3056214A1 (en) 2016-08-17
US11896666B2 (en) 2024-02-13
PL3056214T3 (pl) 2019-09-30
US20170304434A1 (en) 2017-10-26
CA2960846A1 (en) 2009-12-30
HK1211870A1 (en) 2016-06-03
JP2017061484A (ja) 2017-03-30
US12521433B2 (en) 2026-01-13
US20240358825A1 (en) 2024-10-31
CL2010001360A1 (es) 2011-04-08
AU2009263759B2 (en) 2013-06-06
TW201014601A (en) 2010-04-16
CA2960734C (en) 2021-08-24
EP3552625A1 (en) 2019-10-16
JP5882370B2 (ja) 2016-03-09
WO2009156960A3 (en) 2010-06-17
EP3056214B1 (en) 2019-04-03
US20190008953A1 (en) 2019-01-10
US20140056940A1 (en) 2014-02-27
US9662385B2 (en) 2017-05-30
CY1121789T1 (el) 2020-07-31
TWI614027B (zh) 2018-02-11
LT3056214T (lt) 2019-06-10
BR122021025097B1 (pt) 2022-07-26
NZ727616A (en) 2018-06-29
MX349720B (es) 2017-08-09
SI2310046T1 (sl) 2016-05-31
PL2310046T3 (pl) 2016-09-30
TWI513464B (zh) 2015-12-21
HUE043493T2 (hu) 2019-08-28
CY1117650T1 (el) 2017-04-26
JP2014111619A (ja) 2014-06-19
CN104758929A (zh) 2015-07-08
JP5824538B2 (ja) 2015-11-25
JP2011525911A (ja) 2011-09-29
PT3056214T (pt) 2019-06-12
CA2723786C (en) 2020-04-28
JP2014111620A (ja) 2014-06-19
CN102076358A (zh) 2011-05-25
ES2569907T3 (es) 2016-05-13
PH12014501836A1 (en) 2016-03-07
RU2010149495A (ru) 2012-08-10
TW201540311A (zh) 2015-11-01
ME01199B (me) 2013-03-20
MX344311B (es) 2016-12-13
JP6038211B2 (ja) 2016-12-07
MX375202B (es) 2025-03-06
WO2009156960A2 (en) 2009-12-30
BRPI0913954B1 (pt) 2022-04-05
MX2010014026A (es) 2011-02-15
US10940202B2 (en) 2021-03-09
TWI622401B (zh) 2018-05-01
ZA201007835B (en) 2012-01-25
JP5659332B2 (ja) 2015-01-28
HK1201444A1 (zh) 2015-09-04
EP2310046B1 (en) 2016-03-09
HK1201445A1 (en) 2015-09-04
AR072378A1 (es) 2010-08-25
NZ621834A (en) 2015-10-30
DK3056214T3 (da) 2019-05-13
US20090324641A1 (en) 2009-12-31
KR101333852B1 (ko) 2013-11-27
TW201544122A (zh) 2015-12-01
CA2960846C (en) 2020-08-25
JP2015143244A (ja) 2015-08-06
CN104001170A (zh) 2014-08-27
US20210338810A1 (en) 2021-11-04
US8580280B2 (en) 2013-11-12
MX368220B (es) 2019-09-24
EP3725328A2 (en) 2020-10-21
RU2510280C2 (ru) 2014-03-27

Similar Documents

Publication Publication Date Title
DK2310046T3 (da) Hidtil ukendte adjuvanssammensætninger
DK2634231T3 (da) Sammensætninger
BRPI0906749A2 (pt) Composição
BRPI0913808A2 (pt) composição
ATE550415T1 (de) Waschzusammensetzung
SMT201600307B (it) Composizione liposomiale
DE602008002756D1 (de) Bauzusammensetzung
DK3078664T3 (da) Antiparasitiske dihydroazol-sammensætninger
EP2488022A4 (en) Compositions
BR112012007952A2 (pt) composição detergente
BRPI0917231A2 (pt) composição
BRPI1013588A2 (pt) composição
UY33161A (es) Composiciones plaguicidas
DOP2011000396A (es) Composiciones novedosas
EP2381760A4 (en) CORN PROTEIN COMPOSITION
ES2628203T8 (es) Composiciones antitranspirantes
FR2933868B1 (fr) Compositions cosmetiques
IT1392101B1 (it) Composizione comprendente isoflavoni
EP2455446A4 (en) CLEANING AGENT COMPOSITION
BRPI1015474A2 (pt) composição
BR112012005039A2 (pt) Composição detergente
BRPI1010690A2 (pt) composições
BRPI0913606A2 (pt) composição detergente
EP2280032A4 (en) PHOTOPOLYMERIZABLE COMPOSITIONS
BRPI0923253A2 (pt) composições depilatória